• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

FENNEC PHARMACEUTICALS INC (FRX)

Equity
Sell: 12.2 CAD|Buy: 12.64 CAD|Change: 0.22 (-1.72%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Address

68 TW Alexander Drive
P.O Box 13628
Research Triangle Park
NC
CAN
27709

Telephone

+1 919 6364530

Website

https://www.fennecpharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Fennec Pharmaceuticals Inc Annual Report for 20242025-03-28T00:00:00
Fennec Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-03-21T08:30:00
Fennec Pharmaceuticals Inc Fourth Quarter Earnings Results for 20242025-03-21T00:00:00
Fennec Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-06T08:30:00
Fennec Pharmaceuticals Inc Third Quarter Earnings Results for 20242024-11-06T00:00:00
Fennec Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-08-02T08:30:00
Fennec Pharmaceuticals Inc Second Quarter Earnings Results for 20242024-08-02T00:00:00
Fennec Pharmaceuticals Inc Annual General Meeting for 20242024-06-12T10:00:00
Fennec Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-10T08:30:00
Fennec Pharmaceuticals Inc First Quarter Earnings Results for 20242024-05-10T00:00:00

Previous key dates

NameKey Date
Fennec Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-10T08:30:00
Fennec Pharmaceuticals Inc First Quarter Earnings Results for 20242024-05-10T00:00:00
Fennec Pharmaceuticals Inc Annual Report for 20232024-03-29T00:00:00
Fennec Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20232024-03-21T08:30:00
Fennec Pharmaceuticals Inc Fourth Quarter Earnings Result for 20232024-03-21T00:00:00
JEFFERIES LONDON HEALTHCARE CONFERENCE 20232023-11-16T17:00:00
Fennec Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20232023-11-06T08:30:00
Fennec Pharmaceuticals Inc Third Quarter Earnings Result for 20232023-11-06T00:00:00
CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 20232023-09-27T15:35:00
Fennec Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20232023-08-03T08:30:00
Fennec Pharmaceuticals Inc Second Quarter Earnings Result for 20232023-08-03T00:00:00
Fennec Pharmaceuticals Inc Annual General Meeting for 20232023-06-12T10:00:00
Fennec Pharmaceuticals Inc First Quarter Earnings Conference Call for 20232023-05-11T08:30:00
Fennec Pharmaceuticals Inc First Quarter Earnings Result for 20232023-05-11T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.